RT Journal Article
SR Electronic
T1 AI coupled to pharmacometric modelling to tailor malaria and tuberculosis treatment in Africa
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.11.07.24316884
DO 10.1101/2024.11.07.24316884
A1 Turon, Gemma
A1 Mulubwa, Mwila
A1 Montaner, Anna
A1 Njoroge, Mathew
A1 Chibale, Kelly
A1 Duran-Frigola, Miquel
YR 2024
UL http://medrxiv.org/content/early/2024/11/07/2024.11.07.24316884.abstract
AB Africa’s vast genetic diversity poses challenges for optimising drug treatments in the continent, which is exacerbated by the fact that drug discovery and development efforts have historically been performed outside Africa. This has led to suboptimal therapeutic outcomes in African populations and overall scarcity of relevant pharmacogenetic data, including characteristic genotypes as well as drugs prescribed in the continent to treat infectious diseases. Here, we propose a general approach to identify drug-gene pairs with potential pharmacogenetic interest. Furthermore, we delve deeper into the analysis of malaria and tuberculosis therapies, many of which remain uncharacterised from a pharmacogenetic perspective. Our pipeline leverages artificial intelligence and the latest advances in knowledge embedding techniques to exploit currently available biomedical data and subsequently prioritise pharmacogenes for each drug. Predicted pharmacogenes are then incorporated into pharmacometric modelling to hypothesise which ones might be of clinical interest, and which dose adjustments could be made to provide better treatment outcomes for the African population.Competing Interest StatementThe authors have declared no competing interest.Funding StatementResearch reported in this publication was supported by the South African Medical research Council (SAMRC) with funds received from Novartis and GSK R&D for Project Africa GRADIENT (Grant # GSKNVS1/202101/004).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All source data was available before the initiation of the project and can be found in the following databases: 1000Genomes (https://www.internationalgenome.org/data) and PharmGKB (https://www.pharmgkb.org/downloads)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll PGx data used in the study has been curated from the publicly available resource PharmGKB, accessed in January, 2024. Curated data is available in the https://github.com/ersilia-os/pharmacogx-embeddings. Data related to genomic variants has been curated from the 1000 Genomes project and is available in https://github.com/ersilia-os/pharmacogx-arsa.